IN2014DN09826A - - Google Patents
Info
- Publication number
- IN2014DN09826A IN2014DN09826A IN9826DEN2014A IN2014DN09826A IN 2014DN09826 A IN2014DN09826 A IN 2014DN09826A IN 9826DEN2014 A IN9826DEN2014 A IN 9826DEN2014A IN 2014DN09826 A IN2014DN09826 A IN 2014DN09826A
- Authority
- IN
- India
- Prior art keywords
- psychiatric
- schizophrenia
- neurodegenerative
- mammals
- compounds
- Prior art date
Links
- 241000124008 Mammalia Species 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 230000007278 cognition impairment Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 230000000626 neurodegenerative effect Effects 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- Communicable Diseases (AREA)
- Endocrinology (AREA)
- Anesthesiology (AREA)
- Obesity (AREA)
Abstract
Compounds of Formula (I), wherein R1, R 2, X 1, Y1, Z1, and Z2, are as defined herein , and pharmaceutically acceptable salts thereof , are described as useful for the treatment of cognitive deficits associated with schizophrenia and other psychiatric, neurodegenerative and/or neurological disorders in mammals , including humans.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261660142P | 2012-06-15 | 2012-06-15 | |
| PCT/IB2013/054570 WO2013186666A1 (en) | 2012-06-15 | 2013-06-03 | Tricyclic compounds as kat ii inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN09826A true IN2014DN09826A (en) | 2015-07-31 |
Family
ID=48875701
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN9826DEN2014 IN2014DN09826A (en) | 2012-06-15 | 2014-11-19 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20150175603A1 (en) |
| EP (1) | EP2861593A1 (en) |
| JP (1) | JP2015523352A (en) |
| KR (1) | KR20150007352A (en) |
| CN (1) | CN104364253A (en) |
| AU (1) | AU2013276165B2 (en) |
| BR (1) | BR112014030507A2 (en) |
| CA (1) | CA2874400A1 (en) |
| HK (1) | HK1206734A1 (en) |
| IL (1) | IL236241A0 (en) |
| IN (1) | IN2014DN09826A (en) |
| MX (1) | MX2014014808A (en) |
| RU (1) | RU2014146509A (en) |
| SG (1) | SG11201407389QA (en) |
| WO (1) | WO2013186666A1 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106661017B (en) | 2014-04-23 | 2019-09-24 | 田边三菱制药株式会社 | Bicyclic or tricyclic heterocyclic compounds |
| CN106349241B (en) * | 2015-07-15 | 2020-04-21 | 上海翰森生物医药科技有限公司 | Triazole derivatives with HSP90 inhibitory activity and preparation method and application thereof |
| US10793582B2 (en) | 2015-10-22 | 2020-10-06 | Mitsubishi Tanabe Pharma Corporation | Bicyclic heterocyclic compound |
| CA3106752A1 (en) | 2018-07-20 | 2020-01-23 | Grunenthal Gmbh | Substituted triazolo quinoxaline derivatives |
| CN111196817B (en) * | 2018-11-19 | 2021-06-11 | 四川大学华西医院 | Tricyclic compounds as BRPF1 inhibitors |
| TWI880049B (en) * | 2020-12-04 | 2025-04-11 | 美商美國禮來大藥廠 | Kras g12c inhibitors |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2316072B (en) * | 1996-08-05 | 2000-05-10 | Pharmacia Spa | Pyrrolo[3,2-c]quinoline derivatives |
| ES2538386T3 (en) * | 2009-06-18 | 2015-06-19 | Pfizer Inc. | Bicyclic and tricyclic compounds as inhibitors of KAT II |
| SG190246A1 (en) * | 2010-12-01 | 2013-06-28 | Pfizer | Kat ii inhibitors |
-
2013
- 2013-06-03 CN CN201380031450.0A patent/CN104364253A/en active Pending
- 2013-06-03 JP JP2015516713A patent/JP2015523352A/en active Pending
- 2013-06-03 EP EP13742050.1A patent/EP2861593A1/en not_active Withdrawn
- 2013-06-03 SG SG11201407389QA patent/SG11201407389QA/en unknown
- 2013-06-03 KR KR1020147034987A patent/KR20150007352A/en not_active Withdrawn
- 2013-06-03 CA CA2874400A patent/CA2874400A1/en not_active Abandoned
- 2013-06-03 RU RU2014146509A patent/RU2014146509A/en not_active Application Discontinuation
- 2013-06-03 US US14/405,103 patent/US20150175603A1/en not_active Abandoned
- 2013-06-03 BR BR112014030507A patent/BR112014030507A2/en not_active IP Right Cessation
- 2013-06-03 MX MX2014014808A patent/MX2014014808A/en unknown
- 2013-06-03 WO PCT/IB2013/054570 patent/WO2013186666A1/en not_active Ceased
- 2013-06-03 HK HK15107294.1A patent/HK1206734A1/en unknown
- 2013-06-03 AU AU2013276165A patent/AU2013276165B2/en not_active Expired - Fee Related
-
2014
- 2014-11-19 IN IN9826DEN2014 patent/IN2014DN09826A/en unknown
- 2014-12-14 IL IL236241A patent/IL236241A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2014014808A (en) | 2015-02-12 |
| RU2014146509A (en) | 2016-08-10 |
| CA2874400A1 (en) | 2013-12-19 |
| HK1206734A1 (en) | 2016-01-15 |
| SG11201407389QA (en) | 2015-02-27 |
| IL236241A0 (en) | 2015-02-01 |
| CN104364253A (en) | 2015-02-18 |
| BR112014030507A2 (en) | 2017-06-27 |
| AU2013276165A1 (en) | 2014-11-27 |
| KR20150007352A (en) | 2015-01-20 |
| AU2013276165B2 (en) | 2015-07-16 |
| WO2013186666A1 (en) | 2013-12-19 |
| US20150175603A1 (en) | 2015-06-25 |
| EP2861593A1 (en) | 2015-04-22 |
| JP2015523352A (en) | 2015-08-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020013099A (en) | Heteroaromatic compounds and their use as dopamine d1 ligands. | |
| WO2014106238A8 (en) | Heterocyclic compounds and methods of use thereof | |
| PH12015502658A1 (en) | 3,4-dihydroisoquinolin-2 (1h)-yl compounds | |
| MX347917B (en) | Imidazo [1, 2 - b] pyridazine - based compounds, compositions comprising them, and uses thereof. | |
| HRP20180678T1 (en) | [1,2,4] TRIAZOLE [1,5-C] QUINAZOLINE-5-AMINE COMPOUNDS SUBSTITUTED BY HETEROBICYCLE SUITABLE FOR THE TREATMENT OR PREVENTION OF CENTRAL NERVOUS DISORDERS | |
| TN2012000369A1 (en) | 5-alkynyl-pyrimidines | |
| MX2015001720A (en) | Substituted hetero-azepinones. | |
| MX2015007097A (en) | Novel bi-ring phenyl-pyridines/pyrazines for the treatment of cancer. | |
| GEP20166554B (en) | Nitrogenated heterocyclic compound | |
| MX2011013870A (en) | Bicyclic and tricyclic compounds as kat ii inhibitors. | |
| MD20150023A2 (en) | Novel bicyclic pyridinones | |
| IN2014DN09826A (en) | ||
| PH12016501863A1 (en) | Heteroaromatic compounds and their use as dopamine d1 ligands | |
| PH12016501993A1 (en) | Heteroaromatic compounds and their use as dopamine d1 ligands | |
| TN2012000191A1 (en) | Quinuclidine compounds as alpha-7nicotinic acetylcholine receptor ligands | |
| JO3483B1 (en) | 4-hydroxy-2-methyl-5-(propan-2-ylidene)cyclohex-3-enecarbaldehyde for the prevention and treatment of a cognitive, neurodegenerative or neuronal disease | |
| IN2012DN06600A (en) | ||
| HK1199014A1 (en) | Mglu 2/3 agonists | |
| CA2863110A1 (en) | 1,2- pyridazine, 1,6- pyridazine or pyrimidine - benzamide derivatives as gpbar1 modulators | |
| GB201206984D0 (en) | New therapeutic use | |
| TN2014000303A1 (en) | Mglu 2/3 agonists | |
| GEP201606554B (en) | Nitrogenated heterocyclic compound |